{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/vitiligo/diagnosis/diagnosis/","result":{"pageContext":{"chapter":{"id":"465324e6-d6e2-5263-8c5d-9368e36b2d89","slug":"diagnosis","fullItemName":"Diagnosis","depth":2,"htmlHeader":"<!-- begin field 73d93114-bef7-4c4b-be72-3e9cc17cba85 --><h2>When should I suspect vitiligo?</h2><!-- end field 73d93114-bef7-4c4b-be72-3e9cc17cba85 -->","summary":"","htmlStringContent":"<!-- begin item 7e0b6576-de97-48c4-b377-d1af332bd699 --><!-- begin field aa9f38cd-c153-4717-bbbe-c7b8b99f8533 --><p><strong>Suspect a diagnosis of vitiligo if there are areas of skin (or hair) depigmentation that are usually asymptomatic, but can be itchy at disease onset.</strong></p><ul><li><strong>Lesions are characterised by: </strong><ul><li>Colour<ul><li>Skin macules and patches may initially appear pale and hypopigmented, before eventually becoming chalky white and depigmented. Occasionally, they have a white centre with an intermediate, pale area around (so-called 'trichrome' vitiligo).</li><li>The patches may appear pink in more vascular areas.</li></ul></li><li>Margins<ul><li>Lesions are typically well-demarcated. The borders/margins may be smooth or irregular ('scalloped').</li><li>Occasionally, inflammation is seen at the advancing edge of a lesion.</li></ul></li><li>On palpation<ul><li>Lesions are flat and non-scaly.</li></ul></li><li>Extent and distribution<ul><li>Lesions may be localized or generalized.</li><li>Lesions are often bilateral and symmetrical. They may be unilateral in early <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/background-information/definition/\">non-segmental vitiligo</a>, or in <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/background-information/definition/\">segmental vitiligo</a> when confined to part or all of one or more dermatomes or areas delineated by Blaschko's lines.</li><li>Lesions can appear anywhere, but the sites most commonly affected are the fingers and wrists, axillae, groin, and genitalia, and the skin around the eyes and mouth. Mucosal areas (including the mouth) can be prominent in people with darker skin pigmentation. The fingers, hands, and face are often affected first.</li><li>Vitiligo may exhibit the Koebner phenomenon, with depigmentation developing at sites of mechanical trauma (such as abrasions or burns) or friction (such as waistbands).</li><li>Hair roots can be affected, resulting in white eyelashes and white hair (which may be patchy).</li></ul></li><li>Progression<ul><li>Without treatment, individual lesions usually enlarge over time and patches may merge to form extensive geographical patterns.</li><li>Rarely, vitiligo can spread to cover almost all of the skin.</li></ul></li></ul></li><li>The website DermNet NZ available at <a href=\"https://dermnetnz.org/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"39657250-bd89-4ebd-bade-ab990113dbcf\">www.dermnetnz.org</a> has some useful images of different presentations of vitiligo.</li><li><strong>Suspect an <a class=\"topic-reference internal-reference\" href=\"/topics/vitiligo/diagnosis/differential-diagnosis/\">alternative diagnosis</a> </strong>if there are other clinical features such as scaling, inflammation, induration, skin swelling, or scarring.</li></ul><!-- end field aa9f38cd-c153-4717-bbbe-c7b8b99f8533 --><!-- end item 7e0b6576-de97-48c4-b377-d1af332bd699 -->","topic":{"id":"72501cc1-fbf6-5c3a-bfc1-1a2d865f7dff","topicId":"85a32b0f-cf7a-41c9-9dd8-caed21004663","topicName":"Vitiligo","slug":"vitiligo","lastRevised":"Last revised in April 2020","chapters":[{"id":"237f05d1-6751-5abf-98b0-af49db55e1b3","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e51e2938-3e89-53a6-9251-b0376a90be4d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5c590af0-29e5-5be3-958d-02f67350d529","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"aee2331c-c78c-5c0d-ba9a-c974cfb039ae","slug":"changes","fullItemName":"Changes"},{"id":"8afc6e46-c250-5eb3-85a1-355d3e18ee65","slug":"update","fullItemName":"Update"}]},{"id":"78bbc5cd-9e73-55fb-b421-d718417be14a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1a4f8e76-7634-54ba-8849-3051a448dccc","slug":"goals","fullItemName":"Goals"},{"id":"65dbcf54-b53e-54e8-a2fe-a07b8aae49f2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ba868062-b333-5694-90cb-1b24ed0d9c11","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1912341a-6cf7-5d2a-b20d-cb4f55308c36","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"05992da2-cc78-5880-8307-5a5f8e4cc4da","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"30dc5858-bfd0-5918-b331-9067d9743f12","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"33d1fc44-e925-5b20-982d-7e60d75465ea","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c23ed46f-6f85-51ef-9f34-aea63f9aea9e","slug":"definition","fullItemName":"Definition"},{"id":"cfca1785-6f25-546b-8fba-a9bb5ec8bc4f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1c68db6d-01f9-5407-b229-ad9ba72d53b1","slug":"causes","fullItemName":"Causes"},{"id":"def00a0c-fcf5-5066-b8b6-d4197121b345","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4b6c885f-0d2d-5b2c-abeb-495372e63081","slug":"complications","fullItemName":"Complications"},{"id":"63ac95a4-7b80-5aef-bf7b-cc1b8b812a1c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9b1dd44e-152a-5b47-8bbd-a07a6000032f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"465324e6-d6e2-5263-8c5d-9368e36b2d89","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ebc547bc-2b3a-55f8-a703-fff4f5d4f309","slug":"assessment","fullItemName":"Assessment"},{"id":"dea3c9af-e347-5a61-8a6e-852afbca1f6b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"674a723c-f8af-5b44-b6fc-6d46ad281431","fullItemName":"Management","slug":"management","subChapters":[{"id":"d85da703-7350-5165-a4eb-3697e45db487","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"8ddf3c8a-0168-521b-a940-e841ebe05935","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0f441642-e226-5709-89d2-b4f6eeee7a85","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d538aa6d-327c-503c-b574-69a24bbfd9f0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c5bed09a-eccb-5abe-8ff1-63f178d8c28c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f56b39ed-360e-5ae6-9103-c21bb5e9862d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ba61933a-4f62-5bb3-988b-9749f78e6265","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"31c2bb80-d9f1-5095-b859-2ad42da47934","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a43f071b-fb92-55e3-a42d-348c5fd48924","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9b1dd44e-152a-5b47-8bbd-a07a6000032f","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"7fd4655f-0636-51ce-bf6d-4e70a563cd48","slug":"basis-for-recommendation-a47","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field b8c63397-d871-4966-8e98-bf8377501d45 --><h3>Basis for recommendation</h3><!-- end field b8c63397-d871-4966-8e98-bf8377501d45 -->","summary":null,"htmlStringContent":"<!-- begin item a470a4b3-ed4e-45ad-bbb5-573f3d1755ea --><!-- begin field da169a66-26cd-4fcc-afa8-9a7cfa5ebf4b --><p>The information on when to suspect vitiligo is based on the British Association of Dermatologists (BAD) publication <em>Guideline for the diagnosis and management of vitiligo</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gawkrodger, 2008</a>], the European Dermatology Forum consensus document <em>Guidelines for the management of vitiligo</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Taieb, 2013</a>], and expert opinion in review articles on vitiligo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Gawkrodger, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Bergqvist, 2020</a>], on vitiligo in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Ezzedine, 2016</a>], and on depigmentation disorders [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Mollet, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vitiligo/references/\">Plensdorf, 2017</a>].</p><!-- end field da169a66-26cd-4fcc-afa8-9a7cfa5ebf4b --><!-- end item a470a4b3-ed4e-45ad-bbb5-573f3d1755ea -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}